All Articles In 'Medicaid Drug Benefit'
Medicaid Prescription Drugs: Utilization in Medicaid Health Plans and Medicaid Fee-for-Service
What’s the impact on patient care, particularly prescription drug utilization, as Medicaid beneficiaries move from fee-for-service to Medicaid health plans? This year, state Medicaid programs will spend over $22.1 billion on pharmacy benefits. This will grow to [...]
Electronic Health Records: Best Practices in Washington State Save Medicaid Money
Health information technology, care coordination, and cost containment have increasingly become entwined in health care policy. Medicare and Medicaid both have electronic health record (EHR) incentive programs to encourage physicians, hospitals, and other providers to use [...]
Legality of Pay for Delay Settlements: SCOTUS Pharma and Biotech Case Preview
The 2012 Supreme Court got a lot of attention for its decision to uphold most of the Affordable Care Act (ACA) health reform law in NFIB v. Sebelius. But this year’s court docket will be no [...]
State Medicaid Changes: Cuts and Increases During Recession to Medicaid Benefits and Provider Payments
Medicaid accounts for the largest share of state budgets and is growing still. Since fiscal year 2010, state Medicaid spending nationwide grew from 22.2 percent to about 24 percent of the average state budget, according to [...]
Medicaid Prescription Drugs: National Survey of Average Drug Acquisition Costs
The Centers for Medicare and Medicaid Services (CMS) is working to help state Medicaid programs get the best deal possible when purchasing prescription drugs. The second phase of CMS’s Medicaid retail drug price survey will poll [...]
Medicare Part D and Dual Eligibles: Prescription Drug Formularies and Drugs Used by Dual Eligibles
Medicare Part D prescription drug plan formularies in 2012 covered 96 percent of the drugs most used by people eligible for both full Medicare benefits and Medicaid – full benefit dual eligibles - according to the Department [...]
Pharmaceutical Payment: Pharma and Biotech Market Shifting to Value or Outcomes-Based Drug Revenue Model
Pharmaceutical manufacturers face an economic transformation as payors look more toward value-based – as opposed to transactional, unit-based – models for drug reimbursement. This value-based revenue model presents enormous implications for the future of pharma and biotech, impacting everything [...]
Prescription Drug Pricing: Estimating Generic Drug Cost Savings
Prescription drug spending rose by $135 billion between 2001 and 2010 to comprise approximately 12 percent of the nation’s overall healthcare outlay. While drug expenditure was one of the fastest growing components of U.S. healthcare spending [...]
American Health & Drug Benefits: June 2010 Issue
The latest issue of the journal American Health & Drug Benefits includes a valuable mix of studies and articles of interest to decision makers. Topics include health reform, bundled payment, drug pricing, benefit design, Medicaid, medication [...]
Medicaid Drug Rebate: Expansion of Federally Mandated Prescription Drug Rebates in Medicaid
Federally mandated rebates for prescription drugs in Medicaid were expanded significantly – by $38 billion – under the new health reform law, with extraordinary financial, administrative, and compliance implications for pharmaceutical manufacturers, Medicaid health plans, and [...]
Stay Connected
Managing Editor
